Loading
Every dated change on the records linked to Neuroendocrine tumours, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Histology with Ki-67 grading; 68Ga/64Cu-DOTATATE PET/CT ± FDG PET; triple-phase CT or MRI of the liver; chromogranin A and syndrome-specific hormones; germline testing for pancreatic NETs and paragangliomas. (NCCN Neuroendocrine and Adrenal Tumors)
A milestone in how this cancer is treated.
Advanced pancreatic and extra-pancreatic neuroendocrine tumours after prior therapy (CABINET)
ORR 54.
PFS 23.
A milestone in how this cancer is treated.
PFS HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Advanced non-pancreatic neuroendocrine tumours; pancreatic neuroendocrine tumours from 2021
Neuroendocrine cohort: about one in four responded, concentrated in high-grade disease; angiosarcoma cohort about one in four, mostly cutaneous scalp and face tumours; many other cohorts inactive.
PFS HR 0.
A milestone in how this cancer is treated.
PET localisation of SSTR-positive neuroendocrine tumours (Ga-68 DOTATATE)
A milestone in how this cancer is treated.